Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.52 |
| ▸ | BAD | Q92934 | 2/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70164 | 0.88 | MCL1 (0.66) | MCL1ACMSDDHFRHNF4AKDM4E | |
| Hydrochloric Acid SCHEMBL9153007 | 0.86 | MCL1 (0.63) | MCL1ACMSDDHFRHNF4AKDM4E | |
| SCHEMBL14089891 | 0.85 | RXRB (0.61) | MCL1BCL2L1BADNOTUMACMSD | |
| SCHEMBL10024279 | 0.85 | MCL1 (0.63) | MCL1ACMSDDHFRHNF4AAKR1C2 | |
| SCHEMBL5255978 | 0.85 | MCL1 (0.63) | MCL1ACMSDDHFRHNF4AAKR1C2 | |
| SCHEMBL4966627 | 0.85 | MCL1 (0.70) | MCL1ACMSDDHFRHNF4AKDM4E | |
| SCHEMBL10024256 | 0.84 | DCLRE1B (0.57) | MCL1NOTUMACMSDDHFRHNF4A | |
| SCHEMBL29780492 | 0.84 | KEAP1 (0.59) | MCL1NOTUMACMSDDHFRKDM4E | |
| SCHEMBL145273 | 0.84 | KEAP1 (0.59) | MCL1NOTUMACMSDDHFRKDM4E | |
| SCHEMBL27808113 | 0.83 | BCL2L1 (0.53) | MCL1BCL2L1BADNOTUMACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0693062-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
| WO-1994024116-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | MCL1 4030/4885BCL2L1 4702/4885BAD 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.